Entering text into the input field will update the search result below

Calithera +13% premarket on positive telaglenastat data

  • Calithera Biosciences (NASDAQ:CALA) reports positive results from its Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC).
  • The combination doubled the median progression-free survival (PFS) in heavily pre-treated patients to 3.8 months as compared to 1.9 months for everolimus alone and reduced the risk of disease progression or death by 36%. It also had a well-tolerated safety profile.
  • The primary endpoint of the trial was PFS per investigator assessment with a predetermined threshold of p≤0.2 one-sided. The secondary endpoint of overall survival is not yet mature.
  • Telaglenastat is the first glutaminase inhibitor to demonstrate clinical activity for the treatment of cancer.
  • Shares are up 13% premarket.

Recommended For You

About CALA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CALA--
Calithera Biosciences, Inc.